Search
IMM101
go.drugbank.com/drugs/DB15851ExperimentalAs of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over … 1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19 infection (NCT04442048).
Peginesatide
go.drugbank.com/drugs/DB08894ApprovedWithdrawnChemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. … Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012.
Categories: Compounds used in a research, industrial, or household settingObinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis. … This chemical modification significantly enhances its affinity for FcγRIII receptors on immune effector cells.
Categories: CD20 (Clusters of Differentiation 20) inhibitorsProducts: GAZYVA 1000 MG/ 40 ML CONCENTRATE FOR SOLUTION FOR INFUSION, GAZYVA 1000 MG IV İNFÜZYONLUK KONSANTRE ÇÖZELTİ, 1 ADETSodium cellulose phosphate
go.drugbank.com/drugs/DB06776ApprovedSodium cellulose phosphate is used to treat hypercalcemia and hypercalciuria. It has been used to prevent kidney stones. This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore norm...
Categories: Drugs for Treatment of Hypercalcemia, Compounds used in a research, industrial, or household settingRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalRituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].
Categories: CD20 (Clusters of Differentiation 20) inhibitorsProducts: MABTHERA SOLUCION PARA INFUSION 10 MG/ML, MABTHERA ROCHE SOLUCION PARA INFUSION 10 MG/MLTorasemide
go.drugbank.com/drugs/DB00214ApprovedInvestigationalTorasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Categories: combinations of sulfonamides, Increased Diuresis at Loop of HenleProducts: UNAT (10 MG TABLETS), TORASEMID 1A PHARMA 5 MGButylscopolamine
go.drugbank.com/drugs/DB09300ApprovedInvestigationalVet approvedIt is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. … It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms.
Mixtures: HIOSCINA 20 MG + DIPIRONA 2.5 G, TRANKO-BUSKAS 10 MG + 10 MG KAPLI TABLET, 40 ADETProducts: HYOKEM®10 MG, COLESPAS® 10 MGIobitridol
go.drugbank.com/drugs/DB12407ApprovedWithdrawnIobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.
Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household settingProducts: Xenetix 250 (250 mg Jod/ml) - Parenterale Röntgenkontrastmittellösung, XENETİX 300 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 100 MLLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: LURATA 40 mg Film-Coated Tablet, LURATA 80 mg Film-Coated TabletTetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigational[A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]
Categories: Drugs for Treatment of Hyperkalemia and HyperphosphatemiaProducts: FERRISITA 107,7 MG/5 ML SURUP, 150 ML